We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00365768
First Posted: August 17, 2006
Last Update Posted: September 9, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Julia Glade Bender, Columbia University
  Purpose

RATIONALE: Glutamine may help lessen neuropathy caused by chemotherapy. It is not yet known whether glutamine is more effective than a placebo in treating neuropathy caused by vincristine.

PURPOSE: This randomized phase II trial is studying glutamine to see how well it works compared to a placebo in treating neuropathy caused by vincristine in young patients with lymphoma, leukemia, or solid tumors.


Condition Intervention Phase
Kidney Cancer Leukemia Lymphoma Neurotoxicity Peripheral Neuropathy Sarcoma Drug: Glutamine Other: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Supportive Care
Official Title: A Pilot Study Investigating the Effects of Glutamine and Vincristine-Induced Neuropathy in Pediatric Patients With Cancer

Resource links provided by NLM:


Further study details as provided by Julia Glade Bender, Columbia University:

Primary Outcome Measures:
  • Incidence of Vincristine-induced Peripheral Neuropathy [ Time Frame: Up to 30 weeks from baseline while on Vincristine treatment ]

Secondary Outcome Measures:
  • Number of Participants With Progression of Neuropathy [ Time Frame: 42 days ]

Enrollment: 56
Study Start Date: October 2004
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I: Glutamine
Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21.
Drug: Glutamine
Administered orally twice daily for 21 days
Other Name: Nutritional Supplement
Placebo Comparator: Arm II: Placebo
Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21.
Other: Placebo
Administered orally twice daily for 21 days

Detailed Description:

OBJECTIVES:

Primary

  • Determine the incidence of vincristine-induced peripheral neuropathy in pediatric patients with lymphoma, leukemia, or solid tumors.

Secondary

  • Compare the safety of glutamine vs placebo in these patients.
  • Compare the efficacy of glutamine vs placebo in reducing the progression and/or resolution of vincristine-induced peripheral neuropathy in these patients.
  • Compare the effect of glutamine supplementation vs placebo on chemotherapy-related toxicities in these patients.
  • Compare the effect of glutamine vs placebo on measures of quality of life in these patients.
  • Compare the effect of glutamine supplementation vs placebo on serum nerve growth factor and glutamine levels in these patients.
  • Determine the effect of glutamine on vincristine-mediated antitumor efficacy in vitro.

OUTLINE: This is a randomized, double-blind, placebo-controlled, pilot study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21.
  • Arm II: Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21.

Patients in both arms undergo neuropsychological and clinical neurological assessment, blood collection for serum marker (e.g., serum glutamine and nerve growth factor) analysis, and quality of life assessment on days 1, 21, and 42.

After completion of study treatment, patients are followed for an additional 21 days.

PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   5 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients between the age of 5 and 21 years old.
  • Patients who demonstrate the ability to complete the assessment instruments at baseline.
  • Patients who are diagnosed with leukemia or solid tumors and are expected to receive a cumulative dose of > or = to 6mg/m2 of vincristine, or > 6mg if individual vincristine doses are capped at 2mg according to primary cancer treatment protocol, over a 30-week period.

Exclusion Criteria:

  • Patients with primary CNS tumors other than medulloblastoma or patients with CNS metastasis.
  • Patients with recurrent disease.
  • Patients with Grade II, III or IV neurological status by the NCI CTC (Ver. 3.0) on clinical exam.
  • Patients who have already received > 8mg/m2 of vincristine, or > 8mg if individual vincristine doses are capped at 2mg according to primary cancer treatment protocol, during their course of therapy at time of consent.
  • Patients with hepatic encephalopathy or hyperammonemia.
  • Patients with a focally abnormal neurologic exam.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00365768


Locations
United States, New York
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
Investigators
Principal Investigator: Julia L. Glade-Bender, MD Herbert Irving Comprehensive Cancer Center
  More Information

Responsible Party: Julia Glade Bender, Irving Assistant Professor of Clinical Pediatrics, Columbia University
ClinicalTrials.gov Identifier: NCT00365768     History of Changes
Other Study ID Numbers: AAAA6806
CPMC-ICCR-3349 ( Other Identifier: Columbia University Medical Center )
First Submitted: August 16, 2006
First Posted: August 17, 2006
Results First Submitted: November 6, 2015
Results First Posted: September 9, 2016
Last Update Posted: September 9, 2016
Last Verified: July 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Julia Glade Bender, Columbia University:
stage II childhood lymphoblastic lymphoma
stage III childhood lymphoblastic lymphoma
stage II childhood small noncleaved cell lymphoma
stage I Wilms tumor
stage II Wilms tumor
stage III Wilms tumor
stage IV Wilms tumor
stage V Wilms tumor
childhood grade III lymphomatoid granulomatosis
childhood diffuse large cell lymphoma
childhood immunoblastic large cell lymphoma
stage I childhood large cell lymphoma
stage I childhood lymphoblastic lymphoma
stage I childhood small noncleaved cell lymphoma
stage II childhood large cell lymphoma
stage III childhood large cell lymphoma
stage IV childhood large cell lymphoma
stage IV childhood lymphoblastic lymphoma
stage IV childhood small noncleaved cell lymphoma
childhood Burkitt lymphoma
stage III childhood small noncleaved cell lymphoma
untreated childhood acute lymphoblastic leukemia
childhood nasal type extranodal NK/T-cell lymphoma
previously untreated childhood rhabdomyosarcoma
localized Ewing sarcoma/PNET
metastatic Ewing sarcoma/PNET
neurotoxicity
peripheral neuropathy

Additional relevant MeSH terms:
Lymphoma
Leukemia
Sarcoma
Peripheral Nervous System Diseases
Kidney Neoplasms
Carcinoma, Renal Cell
Neurotoxicity Syndromes
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms, Connective and Soft Tissue
Neuromuscular Diseases
Nervous System Diseases
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Poisoning
Chemically-Induced Disorders
Vincristine
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators